Biopharmaceutical News and Research

RSS

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

...

17 Oct 2013

Imaxio Sells Genomics Division To Hybrigenics

...

16 Oct 2013

SAGE Therapeutics obtains $20M Series B financing from two investors

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat central nervous system (CNS) diseases, today announced a $20 million Series B financing from investors ARCH Venture Partners and Third Rock Ventures, bringing the total raised to $57.8 million since launch in 2011.

16 Oct 2013

Innate Immunotherapeutics moves operations over to Sydney, Australia

Biopharmaceutical company Innate Immunotherapeutics has announced the successful migration of its operations from Auckland, New Zealand to Sydney, Australia.

15 Oct 2013

immatics biotechnologies closes €34 million Series D financing round

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer, today announced that it has closed a €34 million Series D financing round.

15 Oct 2013

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Crown Bioscience, Inc., a leading global drug discovery and development service company, today announces that it has entered into a collaboration with Xstrahl Ltd, a leading designer and manufacturer of X-Ray solutions for radiation biology research.

From Xstrahl 15 Oct 2013

Auxilium Pharmaceuticals gets exclusive right to market VIVUS's STENDRA in the US and Canada

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced today the signing of an agreement with VIVUS, Inc. providing Auxilium with the exclusive right to market VIVUS's product, STENDRA (avanafil), in the United States and Canada.

11 Oct 2013

Constellation Pharmaceuticals awarded grant to facilitate study of epigenetic control of inflammation

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company in the field of epigenetics, today announced that it has been awarded a research grant in collaboration with the University of Pittsburgh School of Medicine from the Cystic Fibrosis Foundation to explore the potential use of BET bromodomain inhibitors for the control of inflammation in cystic fibrosis.

10 Oct 2013

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

Molecular Templates, Inc., a biopharmaceutical company focused on the discovery and development of a new class of biologic therapeutics, announced today that it recently secured an $8.5M series C financing led by Excel Venture Management. Santé Ventures, an existing investor, also participated in the round.

9 Oct 2013

New method for improving cord blood transplant success

Starting with a discovery in zebrafish in 2007, Harvard Stem Cell Institute researchers have published initial results of a Phase Ib human clinical trial of a therapeutic that has the potential to improve the success of blood stem cell transplantation.

9 Oct 2013

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it completed enrollment in a Phase 1 clinical trial of ARC-520, its RNAi-based candidate against chronic hepatitis B virus infection.

9 Oct 2013

Immutep, Eddingpharm partner to develop and commercialize ImmuFact IMP321

Immutep S.A., the biopharmaceutical company specializing in immuno-oncology, and Eddingpharm have entered into an agreement regarding the development, commercialization and manufacturing of Immutep’s ImmuFact IMP321.

7 Oct 2013

Experimental Therapeutics, Debiopharm join to develop oral small molecules targeting new class of epigenetic modulators

The Agency for Science, Technology and Research (A*STAR)'s Experimental Therapeutics Centre (ETC), a center of excellence to advance and accelerate drug discovery in Singapore, and Debiopharm Group™ (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs including oncology as well as companion diagnostics, today announced the signature of an exclusive research collaboration to develop oral small molecules targeting new class of epigenetic modulators.

7 Oct 2013

Kiadis Pharma signs Services Agreement with GRCBDS for Phase II clinical study with ATIR

Kiadis Pharma B.V., a clinical stage biopharmaceutical company developing treatments for blood cancers, announced today that a Services Agreement has been signed with the German Red Cross Blood Donor Service Baden-Wuerttemberg-Hessen (GRCBDS) whereby GRCBDS will provide pharmaceutical development and GMP manufacturing services for Kiadis Pharma's ongoing Phase II clinical study with ATIR™.

7 Oct 2013

EMD Serono announces recipients of company's inaugural Grant for Multiple Sclerosis Innovation

EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today on the occasion of the 29th European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), the recipients of the company's inaugural Grant for Multiple Sclerosis Innovation (GMSI).

7 Oct 2013

Researchers discover way to use stem cells as drug delivery vehicles

A group of Brigham and Women's Hospital, and Harvard Stem Cell Institute researchers and collaborators at MIT and MGH have found a way to use stem cells as drug delivery vehicles.

5 Oct 2013

CureVac collaborates with Janssen on development of influenza vaccine based on mRNA

CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.

3 Oct 2013

Research reveals significant role of Axl receptor in progression, therapeutic resistance of AML

BerGenBio AS, an oncology biopharmaceutical company, announces that a paper entitled "Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine cross-talk of leukemia cells with bone marrow stroma" by Ben-Batalla et al., has been published in Blood, the most cited peer-reviewed research journal in the field of hematology.

1 Oct 2013

Circassia reports positive results from phase II clinical study of ToleroMune grass allergy treatment

Circassia Ltd, a specialty biopharmaceutical company focused on developing world-class immunotherapies, today announced successful results from a large phase II clinical study of its ToleroMune® grass allergy treatment (Grass-Synthetic Peptide Immuno-Regulatory Epitope [Grass-SPIRE])

1 Oct 2013

Merck Canada Gives Patient-Oriented Research $4M Boost

...

30 Sep 2013

Biopharmaceutical News and Research

Astrazeneca, Taiwan's NRPB Launch Drug Discovery Collaboration

Imaxio Sells Genomics Division To Hybrigenics

SAGE Therapeutics obtains $20M Series B financing from two investors

Innate Immunotherapeutics moves operations over to Sydney, Australia

immatics biotechnologies closes €34 million Series D financing round

Crown Bioscience enters into collaboration with Xstrahl for radiation biology research

Auxilium Pharmaceuticals gets exclusive right to market VIVUS's STENDRA in the US and Canada

Constellation Pharmaceuticals awarded grant to facilitate study of epigenetic control of inflammation

Molecular Templates secures $8.5M series C financing plus $10.6M grant from CPRIT

New method for improving cord blood transplant success

Arrowhead initiates Phase 1 study of ARC-520 for treatment against chronic HBV infection

Immutep, Eddingpharm partner to develop and commercialize ImmuFact IMP321

Experimental Therapeutics, Debiopharm join to develop oral small molecules targeting new class of epigenetic modulators

Kiadis Pharma signs Services Agreement with GRCBDS for Phase II clinical study with ATIR

EMD Serono announces recipients of company's inaugural Grant for Multiple Sclerosis Innovation

Researchers discover way to use stem cells as drug delivery vehicles

CureVac collaborates with Janssen on development of influenza vaccine based on mRNA

Research reveals significant role of Axl receptor in progression, therapeutic resistance of AML

Circassia reports positive results from phase II clinical study of ToleroMune grass allergy treatment

Merck Canada Gives Patient-Oriented Research $4M Boost

eBook: Using iPSCs models for human disease research and drug discovery eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News